Sveučilište u Splitu organizira predavanje profesora Paula Brennana, ravnatelja Centra za razvoj lijekova Sveučilišta Oxford i Matthewa Hollanda, doktoranda Sveučilišta Oxford, koje će se održati u ponedjeljak 14. listopada 2024. u 12:15 sati u Vijećnici Senata Sveučilišta u Splitu (Ruđera Boškovića 31, 5. kat).
Očekivano trajanje predavanja je 60 minuta.
Zbog ograničenog broja mjesta obavezna prijava za sudjelovanje preko poveznice:
https://docs.google.com/forms/d/e/1FAIpQLSdyeuSYKu61vhSxb5XzNpuxvnKNEHmWaxJzH76PZnMRpx8QrQ/viewform
https://docs.google.com/forms/d/e/1FAIpQLSdyeuSYKu61vhSxb5XzNpuxvnKNEHmWaxJzH76PZnMRpx8QrQ/viewform
U nastavku možete pronaći opis predavanja:
In the Shadow of the Dreaming Spires - Graduate Research and Life at the University of Oxford
Matthew Holland, Centre for Medicines Discovery, University of Oxford, & Chemistry Research Laboratory, University of Oxford
Founded in 1096, the University of Oxford is the oldest university in the English-speaking world and is home to over 13 000 graduate research students, conducting research in areas ranging from ancient history to zoology. At the heart of this interdisciplinary research is the college structure, which brings together students and academics from a wide variety of subjects and backgrounds. Matthew Holland, a final year doctoral student at Oxford, will outline the history and structure of this unique university, talking through the life of a research student at Oxford, and explaining how its colleges give researchers a new perspective on their subjects.
Modern Methods of Drug Discovery for Alzheimer’s Disease
Professor Paul Brennan, Centre for Medicines Discovery, University of Oxford
There are over 60 million people worldwide living with dementia, and with this figure projected to double every 20 years, there is an urgent need for new treatments and therapies to prevent disease progression and reduce the burden on patients and healthcare systems. Drugging diseases of the brain is traditionally challenging, and there is no exception for neurodegenerative diseases such as Alzheimer’s, where the challenge is exacerbated by the lack of understanding of the underlying causes and mechanisms of disease progression. Professor Brennan, the Director of the Centre for Medicines Discovery (CMD) at the University of Oxford, will outline how recent advances in drug discovery techniques and new insights into the cause of Alzheimer’s Disease are being exploited at the University of Oxford to discover new small-molecule therapeutics for this debilitating disease, and how the unique organisational structure of the CMD enables close partnership with industry to expedite this process.
